// App-Quantinova.ai

CT562 : PARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of Olaparib to Platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients

Researchers

Presenter

  • Lynsey Drewett

Principal Investigators

  • Louise Grybowicz

  • Jerome Wulff

  • Alimu Dayimu

  • Nikolaos Demiris

  • Rebecca Lucey

  • Anne-Laure Vallier

  • Wendi Qian

  • Andrea Machin

  • Karen McAdam

  • Rebecca Roylance

  • Ellen R. Copson

  • Anne Armstrong

  • Nicola Levitt

  • Elena Provenzano

  • Marc Tischkowitz

  • Emma McMurtry

  • Helena Earl

  • Jean E. Abraham

Medical Centers

  • University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

  • University of Cambridge, Cancer Research UK Cambridge Institute, Cambridge, United Kingdom

  • Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

  • Cambridge Clinical Cancer Trials Unit, Cambridge, United Kingdom

  • University College London Hospitals NHS Trust, London, United Kingdom

  • Cancer Sciences, University of Southampton, Southampton, United Kingdom

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • Oxford University Hospitals NHS Trust, Oxford, United Kingdom

  • University of Cambridge, Cambridge, United Kingdom

  • EMC2 Clinical Consultancy, Manchester, Manchester, United Kingdom

  • Department of Oncology, University of Cambridge, and NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom

  • The University of Cambridge, Cambridge University Hospitals NHS Foundation Trust and Cambridge and Cancer Research UK Cambridge Centre, Cambridge, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Triple-negative breast cancer

Biomarkers

  • BRCA mutation

Drug/Treatment

  • Olaparib

Outcome

  • N/A

Study Design

  • Randomized

  • Cohort

Phase

  • II/III

Study Id's

  • NCT03150576

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved